These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 485716)

  • 1. Plasma levels of atenolol after haemodialysis in patients with end stage renal disease.
    Rosseel MT; Bogaert MG; Christiaens M; Verpooten GA; De Broe ME
    Arch Int Pharmacodyn Ther; 1979 May; 239(1):176. PubMed ID: 485716
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.
    Flouvat B; Decourt S; Aubert P; Potaux L; Domart M; Goupil A; Baglin A
    Br J Clin Pharmacol; 1980 Apr; 9(4):379-85. PubMed ID: 7378254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative studies with propranolol, verapamil and atenolol in hypertensive dialysis patients].
    Hepp A; Maisch B; Raff U; Hayduk K
    Verh Dtsch Ges Kreislaufforsch; 1977; 43():239. PubMed ID: 613588
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics of atenolol in patients treated with chronic hemodialysis or peritoneal dialysis.
    Campese VM; Feinstein EI; Gura V; Mason WD; Massry SG
    J Clin Pharmacol; 1985; 25(5):393-5. PubMed ID: 4031118
    [No Abstract]   [Full Text] [Related]  

  • 5. Protein binding of atenolol and propranolol to human serum albumin and in human plasma [proceedings].
    Barber HE; Hawksworth GM; Kitteringham NR; Petersen J; Petrie JC; Swann JM
    Br J Clin Pharmacol; 1978 Nov; 6(5):446P-447P. PubMed ID: 728297
    [No Abstract]   [Full Text] [Related]  

  • 6. Bullous dermatosis of end-stage renal disease: a possible association between abnormal porphyrin metabolism and aluminium.
    Gafter U; Mamet R; Korzets A; Malachi T; Schoenfeld N
    Nephrol Dial Transplant; 1996 Sep; 11(9):1787-91. PubMed ID: 8918623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased excretion of nitric oxide in exhaled air of patients with chronic renal failure.
    Matsumoto A; Hirata Y; Kakoki M; Nagata D; Momomura Si; Sugimoto T; Tagawa H; Omata M
    Clin Sci (Lond); 1999 Jan; 96(1):67-74. PubMed ID: 9857108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Kinetics of metipranolol in patients with chronic kidney failure and during hemodialysis].
    Motán J; Mayer O; Spanĕl M
    Vnitr Lek; 1991 Mar; 37(3):285-92. PubMed ID: 1674391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [End-stage renal failure due to diabetic nephropathy].
    Radković O; Dimković N; Radovanović Lj; Lazić N; Radmilović A
    Srp Arh Celok Lek; 1988; 116(7-8):665-73. PubMed ID: 21213427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].
    Stojimirović B; Grujić-Adanja G
    Srp Arh Celok Lek; 1997; 125(5-6):163-7. PubMed ID: 9265238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of correction of acidosis on nutritional status in dialysis patients.
    Walls J
    Miner Electrolyte Metab; 1997; 23(3-6):234-6. PubMed ID: 9387124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lipoprotein oxidation profile in end stage renal disease patients. Role of vitamin C supplementation].
    Ramos R; Gómez-Geriqué N; Martínez-Castelao A
    Nefrologia; 2005; 25(2):178-84. PubMed ID: 15912655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis.
    Don BR; Spin G; Nestorov I; Hutmacher M; Rose A; Kaysen GA
    J Pharm Pharmacol; 2005 Nov; 57(11):1407-13. PubMed ID: 16259772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of atenolol in relation to renal function.
    Kirch W; Köhler H; Mutschler E; Schäfer M
    Eur J Clin Pharmacol; 1981 Jan; 19(1):65-71. PubMed ID: 7461026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis.
    Evans AM; Faull R; Fornasini G; Lemanowicz EF; Longo A; Pace S; Nation RL
    Clin Pharmacol Ther; 2000 Sep; 68(3):238-49. PubMed ID: 11014405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis.
    Bain MA; Faull R; Fornasini G; Milne RW; Evans AM
    Nephrol Dial Transplant; 2006 May; 21(5):1300-4. PubMed ID: 16401621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recovery of renal function in end-stage renal failure--comparison between peritoneal dialysis and haemodialysis.
    Macdonald JA; McDonald SP; Hawley CM; Rosman J; Brown F; Wiggins KJ; Bannister K; Johnson DW
    Nephrol Dial Transplant; 2009 Sep; 24(9):2825-31. PubMed ID: 19443649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorimetric determination of atenolol in plasma and urine by direct evaluation of thin-layer chromatograms.
    Schäfer M; Mutschler E
    J Chromatogr; 1979 Feb; 169():477-81. PubMed ID: 536437
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetics of mezlocillin during haemodialysis.
    Thorsteinsson SB; Steingrimsson O; Asmundsson P; Bergan T
    Scand J Infect Dis Suppl; 1981; 29():59-63. PubMed ID: 6458883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-dialysis retention of blood lipoproteins and apolipoproteins in patients with end-stage renal disease on maintenance haemodialysis in Kuwait.
    Al-Rashidi M; Hussain AA; Nampoory MR; Al-Ali JH; Akanji AO
    Clin Chim Acta; 2004 Jun; 344(1-2):149-54. PubMed ID: 15149883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.